Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Experts Comment on the GI/GU Cancer FDA Approvals From 2024

February 10th 2025

Experts provide insights on the 2024 FDA approvals in the gastrointestinal and genitourinary fields in this list featuring all the regulatory decisions.

Dr Nguyen on Updated NCCN Guidelines for Non–Clear Cell RCC

February 7th 2025

Charles B. Nguyen, MD, discusses the updated 2024 NCCN Guidelines and their effect on treatment decisions for non–clear cell RCC.

Dr Choueiri on the Significance of Targeting HIF-2α With NKT2152 in ccRCC

January 29th 2025

Toni K. Choueiri, MD, discusses the significance of targeting HIF-2α using NKT2152 in previously treated advanced clear cell renal cell carcinoma.

Dr Zakharia on Long-Term Benefit With Nivolumab Plus Ipilimumab in ccRCC

January 28th 2025

Yousef Zakharia, MD, discusses the long-term benefits of nivolumab plus ipilimumab according to risk status in clear cell renal cell carcinoma.

NKT2152 Ushers in a New Era of HIF-2α Inhibition in Pretreated Advanced ccRCC

January 28th 2025

Toni Choueiri, MD, discusses the unique features of NKT2152, the agent’s safety profile in RCC, and future research directions across GU oncology.

Dr Dizman on the Rationale of Evaluating CBM588 in Metastatic RCC

January 27th 2025

Nazli Dizman, MD, explains the rationale for evaluating the impact of CBM588 on the gut microbiome in patients with metastatic RCC.

FDA Grants Priority Review to Belzutifan for Advanced Pheochromocytoma and Paraganglioma

January 27th 2025

The FDA has granted priority review to belzutifan for advanced pheochromocytoma and paraganglioma.

The OncFive: Top Oncology Articles for the Week of 1/19

January 25th 2025

Treosulfan wins FDA approval for allHCT conditioning in AML and MDS, RP1/nivolumab gets priority review in melanoma, and more this week from OncLive.

Dr Singer on Choosing Between Frontline IO/IO and IO/TKI Regimens in RCC

January 23rd 2025

Adam E. Singer, MD, PhD, discusses factors that inform the choice between IO/IO and IO/TKI regimens for patients with renal cell carcinoma.

Dr McGregor on Future Biomarker Analyses With Nivolumab Plus Ipilimumab in Bladder Cancer

January 23rd 2025

Bradley McGregor, MD, discusses next steps for research with ipilimumab plus nivolumab for patients with diverse bladder cancer histologies.

Dr Braun on Future Directions for Research Into Protein Glycosylation in RCC

January 22nd 2025

David A. Braun, MD, PhD, discusses future directions for research into protein glycosylation as a biomarker of response in renal cell carcinoma.

Felix Y. Feng, MD, Leading Radiation Oncologist and Genitourinary Cancer Researcher, Dies at 48

January 22nd 2025

Felix Y. Feng, MD, a radiation oncologist and researcher at UCSF, died of cancer on December 10, 2024, at 48 years old.

Dr Braun on Protein Glycosylation as a Potential Biomarker of Response in RCC

January 20th 2025

David A. Braun, MD, PhD, discusses the potential use of protein glycosylation as a biomarker of response in renal cell carcinoma.

Dr McGregor on the Potential Use of Checkpoint Inhibitors in Rare GU Cancers

January 20th 2025

Bradley McGregor, MD, discusses the rationale for investigating nivolumab plus ipilimumab in advanced, rare genitourinary malignancies.

Dr Badami on the Optimal Selection of Second-Line TKIs in ccRCC

January 16th 2025

Ami Umesh Badami, MD, discusses clinical research that has informed treatment selection in the second-line clear cell renal cell carcinoma setting.

Dr Westbrook on Clinical Trials That Have Shaped the Non-ccRCC Treatment Paradigm

January 16th 2025

Thomas Westbrook, MD, discusses the non–clear cell renal cell carcinoma research that informs his clinical practice.

Nivolumab Plus Ipilimumab May Offer Efficacious Therapeutic Approach in Rare GU Cancers

January 15th 2025

Bradley McGregor, MD, discusses the findings from a phase 2 study of nivolumab plus ipilimumab in rare GU cancers.

Phase 3 RCC Data Reinforce Efficacy of Standard IO/TKI Doublets Across IMDC Risk Groups

January 15th 2025

Yousef Zakharia, MD, spotlights findings from 3 key trials informing the use of standard IO/TKI regimens in metastatic clear cell renal cell carcinoma.

Selecting Checkpoint Inhibitor–Based Regimens in Clear Cell RCC Requires Several Considerations

January 14th 2025

Yousef Zakharia, MD, discusses the evolving use of checkpoint inhibitors and emerging triplet regimens in clear cell renal cell carcinoma.

Dr Tan on the Efficacy and Safety of IO-IO and IO-TKI Combination Regimens in RCC

January 11th 2025

Alan Tan, MD, discusses the IO-based combination therapies that are available for the treatment of patients with RCC.